ClinicalTrials.gg
CompletedNCT04380519Updated Jan 24, 2022Results posted

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

A Phase 2/3 interventional study of RPH-104 80 mg and Olokizumab 64 mg in COVID-19, sponsored by R-Pharm International, LLC. Completed at 16 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-24.

Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
372
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in COVID-19 with a site in Russian Federation — 4 open to participants now, 9 under way, 1 of them phase 3. COVID-19 · Russian Federation.

Enrollment
33rd of 105
372 · median 198
Started
2020
with 85 others
Phase 2/3
11 of 144
none open now
Registered
9th of 144
by date

Among the 144 studies in COVID-19 with a site in Russian Federation, this one is the 33rd largest by enrollment of the 105 interventional ones that give a count, is one of 86 that started in 2020, is one of 11 in phase 2/3, and was the 9th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 144 studies in COVID-19 with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in COVID-19 with a site in Russian Federation, or all of them as a file.
02

Study summary

The primary objective of the study was to evaluate the efficacy and safety of a single dose of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 15 of the study.

Read the detailed description

The study consisted of two phases:

  • Pilot phase: the first 189 patients were randomized in three groups to receive OKZ, RPH-104 (63 patients per group), followed by an interim analysis of efficacy and safety data.
  • The main phase was the conduct of all procedures prespecified in the protocol. Based on results of interim analysis no changes were made regarding the sample size or primary efficacy endpoint.

For each patient the study included the following periods:

  • Screening period for no more than 48 hours before the start of the day of randomization (Day 1). During the screening period, an assessment was performed to determine whether the patient met the eligibility criteria;
  • Treatment period lasting from the end of the screening (considered as the beginning of the Day 1) to 23:59 of the Day 1, including randomization of the patients in the treatment groups and then a single administration of the study drug;
  • Follow-up period lasting from 00:00 of the Day 2 to 23:59 of the Day 29, including an assessment of the efficacy and safety after administration of the study drug.

Eligible patients were randomized to one of three treatment groups to receive a single subcutaneous injection: RPH-104 80 mg, OKZ 64 mg or placebo in addition to standard care for patients with COVID-19 as per the routine practice in participating facilities. Further, during the term of hospitalization, the clinical observation was performed (Day 1 - Day 15 of the Last Hospitalization Day (LHD), whichever comes first). This was followed by a follow-up period from the from Day 15 or LHD (whichever comes first) to Day 29.

Standard COVID-19 therapy, as per the institution routine practice, was permitted during the study, except the prohibited protocol medication (during the whole period of the study) and tocilizumab and sarilumab (during the first 24 hours after the study treatment administration).

In the absence of positive dynamics in the patient's condition (as per Investigator's judgement), it was possible to administrate a single dose of tocilizumab or sarilumab (in accordance with the actual recommendations), after the 24 hours from one of the study drug's administration.

On Day 15 primary endpoint of patient's clinical status (response to the study therapy) was assessed. The response to the therapy was considered as improvement of the patient's clinical status by at least 1 point on a 6-point COVID-19 scale in the absence of tocilizumab or sarilumab administration.

The last patient's visit in the study was the visit on Day 29. If the patient was discharged from the hospital earlier than Day 15 or Day 29, patient's clinical status at these visits were assessed by phone call.

The total expected duration of the study for each patient was not more than 31 days, including 48 hours of screening, 1 day of the study drug administration and 28 days of observation.

03

Conditions studied

  • COVID-19

Keywords

  • SARS-CoV-2
  • Severe acute respiratory syndrome coronavirus 2
  • 2019-nCoV
  • 2019 novel coronavirus
  • Respiratory disease
  • lung disease
  • COVID-19
  • coronavirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The presence of a voluntarily signed and dated Patient Form for participation in this study, or a record of an Medical Consilium decision justifying patient's participation in case of patient is unable to state his/her will.
  2. Having either of the following COVID-associated respiratory syndromes:

    • pneumonia with oxygenation saturation SpO2 ≤93% (on room air) or respiratory rate greater than 30/min;
    • Acute respiratory distress syndrome (ARDS) ( PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤ 315 if PaO2 is not available).
  3. COVID-19 diagnosis based on:

    • laboratory-confirmed SARS-CoV-2 infection as determined by Polymerase Chain Reaction method (PCR).

OR

  • Bilateral changes in the lungs typical for COVID-19, based on chest computed tomography results.

Exclusion criteria

Exclusion criteria:

  1. A history of to the study drugs (RPH-104 and/or OKZ), and/or their components.
  2. The presence of any of the following laboratory abnormalities:

    • \< 0.5 x 10\^9 L
    • white blood cell count \< 2 x 10\^9 L
    • count \<50 x 10\^9 L
    • (ALT) and/or Aspartate aminotransferase (AST) ≥ 3.0 x (ULN)
  3. Severe renal failure: \< 30 mL/min
  4. Septic shock (vasopressors are required to maintain mean arterial pressure ≥ 65 mm Hg and lactate ≥ 2 mmol/L in the absence of hypovolemia)
  5. The disease progresses to death over the next 24 hours, regardless of treatment, according to Investigator.
  6. Perforation of the gastrointestinal tract, a history of diverticulitis.
  7. Administration of plasma from COVID-19 convalescent donors within 4 weeks before study enrollment and/or planned administration during the study.
  8. Recent (less then 5 half-lives) administration of tocilizumab or sarilumab;
  9. Recent (less then 5 half-lives) or planned during the current study period use of the following drugs:

    • biologics (except RPH-104 or OKZ) with effect, including, but not limited to: Interleukin-1 (IL-1) inhibitors (anakinra, rilonacept, canakinumab), IL- 6 inhibitors (except tocilizumab and sarilumab), IL-17A inhibitors (secukinumab), tumor necrosis factor α (TNFα) inhibitors (infliximab, adalimumab, etanercept, etc.), antiB-cell drugs, etc.
    • other immunosuppressive drugs (with the exception of methotrexate in a dose of up to 25 mg/week), including, but not limited to:

      1. high doses of (equivalent to prednisolone > 1 mg/kg) orally or parenterally;
      2. Janus kinase (JAK) kinase inhibitors; cyclophosphamide, etc.
  10. Concurrent participation in another clinical trial.
  11. Pregnancy, breastfeeding.
  12. A history of active tuberculosis, or active tuberculosis suspected by the Investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
372 participants (actual)

Study arms

  • Experimental
    RPH -104 80 mg

    Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy

    Drug: RPH-104 80 mg

  • Experimental
    Olokizumab 64 mg

    Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy

    Drug: Olokizumab 64 mg

  • Placebo comparator
    Placebo

    Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy

    Drug: Placebo

Interventions

  • solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

  • solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)

  • DrugPlacebo

    Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package

06

What researchers measure

Primary outcomes

  1. Proportion of Responders in Each Treatment Group

    Proportion of patients, responded to the study therapy, in each of the treatment groups. A responder is a patient who has not received tocilizumab or sarilumab and who has a clinical status improvement of ≥1 point on the 6-point COVID-19 scale (where 1 is the most favorable outcome and 6 is the most undesirable outcome) 15 days after the administration of the study drug: 1. Not hospitalized, no activity limitations. 2. Not hospitalized, limited activity. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, supplemental oxygen with independent breathing. 5. Hospitalized; mechanical ventilation (invasive/non-invasive) or Extracorporeal membrane oxygenation (ECMO). 6. Death.

    Time frame: Day 15

Secondary outcomes

  1. Change Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale

    Changes of patients' clinical status on a 6 points ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) over time. The 6-point ordinal scale included the following categories: 1. Not hospitalized, no activity limitations. 2. Not hospitalized, limited activity. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, supplemental oxygen, with independent breathing. 5. Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO. 6. Death.

    Time frame: from Day 2 until Day 15, Day 29

  2. The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab

    The proportion of patients with an improvement in clinical status by 2 or more points on the 6-point ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) during the study with no use of tocilizumab or sarilumab. The 6-point ordinal scale included the following categories: 1. Not hospitalized, no activity limitations. 2. Not hospitalized, limited activity. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, supplemental oxygen, with independent breathing. 5. Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO. 6. Death.

    Time frame: Day 29

  3. The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study

    The proportion of patients who received tocilizumab or sarilumab for COVID-19 during the study

    Time frame: from Day 2 until the Day 29

  4. Mortality Rate During the Study

    Mortality rate over the follow-up period of the study

    Time frame: from Day 1 until Day 29

07

Results

Posted Jan 24, 2022

Participant flow

Enrollment was conducted at 16 clinical sites in Russian Federation. 381 subjects were screened and 372 subjects were enrolled (randomized). A total of 371 subjects were treated, and 336 subjects completed the study. A total of 372 subjects were analyzed for efficacy in the Intent-to-Treat (ITT) Population, 352 subjects in the modified ITT Population (mITT) and 371 subjects were analyzed for safety in the Safety Population.

Participant flow — Overall Study
MilestoneRPH -104 80 mgOlokizumab 64 mgPlacebo
Started124124124
Intent-to-treat (itt)124124124
Modified intent-to-treat (mitt)115119118
Safety population123124124
Completed106113117
Not completed18117
Withdrew: Withdrawal by subject401
Withdrew: Death1496
Withdrew: Adverse event010
Withdrew: Relatives' decision010

Outcome measures

PrimaryProportion of Responders in Each Treatment Group

Proportion of patients, responded to the study therapy, in each of the treatment groups. A responder is a patient who has not received tocilizumab or sarilumab and who has a clinical status improvement of ≥1 point on the 6-point COVID-19 scale (where 1 is the most favorable outcome and 6 is the most undesirable outcome) 15 days after the administration of the study drug: 1. Not hospitalized, no activity limitations. 2. Not hospitalized, limited activity. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, supplemental oxygen with independent breathing. 5. Hospitalized; mechanical ventilation (invasive/non-invasive) or Extracorporeal membrane oxygenation (ECMO). 6. Death.

Time frame:
Day 15
Reported as:
Count of participants · Participants
Proportion of Responders in Each Treatment Group
ParticipantsRPH -104 80 mgOlokizumab 64 mgPlacebo
Proportion of Responders in Each Treatment Group889887
Statistical analysis
  • RPH -104 80 mg vs Placebo · Maximal Likelihood Estimator (MLE) model · p = 0.434 (Hochberg adjustment was applied for p-values) · Risk ratio (rr): 1.012
  • Olokizumab 64 mg vs Placebo · Maximal Likelihood Estimator (MLE) model · p = 0.073 (Hochberg adjustment was applied for p-values) · Risk ratio (rr): 1.125
SecondaryChange Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale

Changes of patients' clinical status on a 6 points ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) over time. The 6-point ordinal scale included the following categories: 1. Not hospitalized, no activity limitations. 2. Not hospitalized, limited activity. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, supplemental oxygen, with independent breathing. 5. Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO. 6. Death.

Time frame:
from Day 2 until Day 15, Day 29
Reported as:
Count of participants · Participants
Change Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale
ParticipantsRPH -104 80 mgOlokizumab 64 mgPlacebo
Day 15 — improvement889996
Day 15 — worsening (including deaths)1387
Day 15 — without change151117
Day 15 — no data864
Day 29 — improvement105113111
Day 29 — worsening (including deaths)1498
Day 29 — without change101
Day 29 — no data424
SecondaryThe Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab

The proportion of patients with an improvement in clinical status by 2 or more points on the 6-point ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) during the study with no use of tocilizumab or sarilumab. The 6-point ordinal scale included the following categories: 1. Not hospitalized, no activity limitations. 2. Not hospitalized, limited activity. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, supplemental oxygen, with independent breathing. 5. Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO. 6. Death.

Time frame:
Day 29
Reported as:
Count of participants · Participants
The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab
ParticipantsRPH -104 80 mgOlokizumab 64 mgPlacebo
The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab9410394
Statistical analysis
  • RPH -104 80 mg vs Placebo · Maximal Likelihood Estimator (MLE) model · p = 0.393 (unadjusted) · Risk ratio (rr): 1.019
  • Olokizumab 64 mg vs Placebo · Maximal Likelihood Estimator (MLE) model · p = 0.061 (unadjusted) · Risk ratio (rr): 1.098
SecondaryThe Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study

The proportion of patients who received tocilizumab or sarilumab for COVID-19 during the study

Time frame:
from Day 2 until the Day 29
Reported as:
Count of participants · Participants
The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study
ParticipantsRPH -104 80 mgOlokizumab 64 mgPlacebo
The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study10515
Statistical analysis
  • RPH -104 80 mg vs Placebo · Risk ratio (rr): 0.67 · 95% CI 0.31 to 1.44
  • Olokizumab 64 mg vs Placebo · Risk ratio (rr): 0.33 · 95% CI 0.12 to 0.89
  • RPH -104 80 mg vs Placebo · Odds ratio (or): 0.64 · 95% CI 0.28 to 1.49
  • Olokizumab 64 mg vs Placebo · Odds ratio (or): 0.31 · 95% CI 0.11 to 0.87
SecondaryMortality Rate During the Study

Mortality rate over the follow-up period of the study

Time frame:
from Day 1 until Day 29
Reported as:
Count of participants · Participants
Mortality Rate During the Study
ParticipantsRPH -104 80 mgOlokizumab 64 mgPlacebo
Mortality Rate During the Study1496
Statistical analysis
  • RPH -104 80 mg vs Placebo · Risk ratio (rr): 2.35 · 95% CI 0.93 to 5.92
  • Olokizumab 64 mg vs Placebo · Risk ratio (rr): 1.5 · 95% CI 0.55 to 4.09
  • RPH -104 80 mg vs Placebo · Odds ratio (or): 2.53 · 95% CI 0.94 to 6.81
  • Olokizumab 64 mg vs Placebo · Odds ratio (or): 1.54 · 95% CI 0.53 to 4.46

Adverse events

Collected over All Adverse Events (AEs), except serious ones, were recorded from the moment of the use of the IP. AEs recorded prior to the start of the study therapy, but after the patient was included in the study, were recorded in the electronic CRF Case report form (eCRF) as "Concomitant diseases". AEs were registered until the end of the follow-up period (day 29).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RPH -104 80 mg14/123 (11.4%)15/123 (12.2%)30/123 (24.4%)
Olokizumab 64 mg9/124 (7.3%)10/124 (8.1%)23/124 (18.5%)
Placebo6/124 (4.8%)8/124 (6.5%)35/124 (28.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventRPH -104 80 mgOlokizumab 64 mgPlacebo
SepsisInfections and infestations3/1232/1243/124
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1233/1240/124
Cardiac failure acuteCardiac disorders2/1230/1240/124
Septic shockInfections and infestations2/1230/1241/124
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders2/1232/1241/124
Type 2 diabetes mellitusMetabolism and nutrition disorders0/1230/1242/124
Atrial fibrillationCardiac disorders1/1230/1240/124
COVID-19Infections and infestations1/1231/1241/124
Viral sepsisInfections and infestations1/1230/1240/124
Cerebral infarctionNervous system disorders1/1230/1240/124
Most frequent other events
Most frequent other events
EventRPH -104 80 mgOlokizumab 64 mgPlacebo
Alanine aminotransferase increasedInvestigations13/12311/12415/124
Aspartate aminotransferase increasedInvestigations12/1239/12412/124
Gamma-glutamyltransferase increasedInvestigations5/1233/1248/124

Baseline characteristics

Age, Continuous
Age, Continuous(years)RPH -104 80 mgOlokizumab 64 mgPlaceboTotal
Mean58.0 (28.0 to 92.0)59.6 (26.0 to 93.0)59.7 (29.0 to 86.0)59.1 (26.0 to 93.0)
Sex: Female, Male
Sex: Female, Male(Participants)RPH -104 80 mgOlokizumab 64 mgPlaceboTotal
Female615857176
Male636667196
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RPH -104 80 mgOlokizumab 64 mgPlaceboTotal
White124123124371
Asian0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RPH -104 80 mgOlokizumab 64 mgPlaceboTotal
Hispanic or Latino1001
Not Hispanic or Latino123123124370
Not reported0101
08

Study locations

16 sites
  • Private healthcare institution "Clinical Hospital" Russian Railways-Medicine named after N. A. Semashko"
    Moscow, 109386, Russian Federation
  • State Budget Healthcare Institution "City Clinical Hospital № 15 named after O.M. Filatov" of Moscow City Healthcare Department
    Moscow, 111539, Russian Federation
  • Federal State Budgetary Institution "Federal Center for Cerebrovascular Pathology and Stroke" of the Ministry of Health of the Russian Federation
    Moscow, 117997, Russian Federation
  • Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University)
    Moscow, 119991, Russian Federation
  • Federal State Autonomous Education Institution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of the Russian Federation (Sechenov University)
    Moscow, 119991, Russian Federation
  • Federal State Budgetary Institution "Central Clinical Hospital with Polyclinic" of Administrative Directorate of the President of the Russian Federation
    Moscow, 121359, Russian Federation
  • Federal State Budget Institution "National Medicine Research Center on Cardiology" By Ministry of Healthcare of Russian Federation
    Moscow, 121552, Russian Federation
  • State Budget Institution of Healthcare "City Clinical Hospital #52", Moscow City Healthcare Department
    Moscow, 123182, Russian Federation
  • State budgetary healthcare institution City Clinical Hospital named after S.I. Spasokukotsky Department of Health of the city of Moscow City Clinical Hospital No. 50
    Moscow, 127206, Russian Federation
  • Moscow State Budget Institution of Healthcare "Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"
    Moscow, 129090, Russian Federation
  • АО "State Company "Medsi" based on Clinical Hospital №1"
    Moscow, 143442, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Volga Research Medical University" of the Ministry of Health of the Russian Federation
    Nizhniy Novgorod, 603950, Russian Federation
  • Saint-Petersburg State Budget Institution of Healthcare "City Hospital №40"
    Saint Petersburg, 197706, Russian Federation
  • Federal Budgetary State Healthcare Institution "National Medical Research Center named after B.A. Almazov"
    Saint-Petersburg, 197341, Russian Federation
  • Budgetary Health Institution Voronezh Regional Clinical Hospital №1
    Voronezh, 394066, Russian Federation
  • State Budget Healthcare Institution of Yaroslavl Region "Yaroslavl Region Clinical Hospital of War Veterans"
    Yaroslavl, 150047, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Jul 2020, 2 months.

Results were first posted in Jan 2022, 1 year 6 months after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 2 months is below that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
May 8, 2020
StartActual
Apr 23, 2020
Primary completionActual
Jul 10, 2020
CompletionActual
Jul 24, 2020
Results first posted
Jan 24, 2022
Last update
Jan 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04380519
Collaborators
Data Management 365, K-Research, LLC
Responsible party
Sponsor
First posted
May 8, 2020
Start date
Apr 23, 2020
Primary completion
Jul 10, 2020
Completion
Jul 24, 2020
Results posted
Jan 24, 2022
Last update
Jan 24, 2022

Study contacts

Mikhail Samsonov
study director · Chief Medical Officer, R-Pharm

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Goflikicept · Olokizumab

Start the discussion